BioNTech (NASDAQ: BNTX) shares fell Friday after the company said it had been informed by partner OncoC4 that FDA placed ...

The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing ...

BioNTech (BNTX) and OncoC4 have had a partial clinical hold placed by the FDA on a Phase 3 study for BNT316/ONC-392 in the ...

The mRNA Revolution When the COVID-19 pandemic struck, the world's medical community initially prepared for a disaster of the scale of the Spanish Flu, which struck during WW1 and killed 50 million ...

mRNA vaccines, pivotal in the fight against COVID-19, are now emerging as a promising innovation in cancer treatment. As ...

The "Global Cancer Vaccines Market - Forecasts from 2024 to 2029" report has been added to ResearchAndMarkets.com's ...

Specialist cancer teams at Castle Hill Hospital in Cottingham are set to offer access to a personalised cancer vaccine for a ...

The companies will collaborate to hold a global Phase I combination trial of YL201 and Amgen’s Imdelltra for small cell lung ...

Medscape Medical News, June 30, 2023 BioNTech, OncoC4 Start Late-Stage Lung Cancer Drug Trial BioNTech and its US partner OncoC4 say they have started a late-stage study of their lung cancer ...

BioNTech has launched global clinical trials for BNT116, an mRNA vaccine designed to treat non-small cell lung cancer. Utilizing the same mRNA technology as Covid-19 vaccines, BNT116 aims to prime ...

Discover why the stock prices of mRNA therapy creators BioNTech and Moderna have plummeted and whether they are still worth ...